Perflubutane microbubbles circulate intravascularly and strongly scatter ultrasound waves, enhancing vascular and tissue perfusion signals. In the liver, the stabilised microbubbles are taken up by Kupffer cells, allowing vascular and postvascular (Kupffer) phase imaging.
Indications / reported uses
Contrast-enhanced ultrasound for evaluation of focal liver lesions in countries where Sonazoid is authorised.
In Japan, also used for selected breast-lesion ultrasound imaging under the relevant product authorisation. The diagnostic agent is the formulated perflubutane microbubble product, not the gas alone.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Perflubutane Environmental Risk Assessment (ERA) (the Perflubutane ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.